Problem
Rapid Reformulation
High IP/IP propellants being phased out in 5-10 years
Complex
Costly, time-consuming reformulation process
Limited IP
Minimal protection for new formulations
Current inhaler products face regulatory pressure to eliminate harmful propellants. Companies struggle with complex reformulation processes and limited IP protection.
Solution
Platform Technology
Rapid formulation screening at low cost with high success rates
Simple
Bypasses complex manufacturing processes
Strong IP
Approved in multiple western countries with ongoing litigation
Our protected technology simplifies the transition to eco-friendly propellants. We've created an efficient path for pharmaceutical companies to develop both generics and new chemical entities.